Efficacy and safety of delayed-release oral mesalazine at 4.8g/D (800mg tablet) in the treatment of moderately active ulcerative colitis: Results of the Ascend III study
Abstract
Efficacy and safety of delayed-release oral mesalazine, moderately active ulcerative colitis